It describes a component that includes a major HER2 antibody linking the second domain of HER2 and a variant of the amino acid sequence therein, including a major amino acid terminal extension. The report also describes drug formulations including cancer treatment ingredients and methods. Requirement 5: Composition of any of the above requirements.The main HER2 antibodies consist of light variable amino acid sequences and heavy variables in ID.3 and 4.Namely 11. Claim 15: Composition of Claim 14In this case, the glycerol variant is selected from the antibody group, which contains a G1 or G2 oligofructose structure and is linked to a FC region.An antibody consisting of carbohydrates is linked to a light chain.An antibody, including a heavy non-glycemic chain,There is also an antigen whose structure is anhydrous and linked to a FC region. Claim 20: Polypeptides, including amino acid sequences in ID 23,Or the same discarded and/or rusted variant Proposition 21: An antibody comprising (a) a light chain of polypeptides contained in Proposition 20.(b) A heavy chain consisting of a series of amino acids selected from the SEC ID 16 group.Ibid., Section 24 and Section 16 or 24 of the International Securities and Exchange Commission are incomplete and/or rusty variants.Se describe una composición que comprende una especie principal de anticuerpo HER2 que se une al dominio II de HER2 y una variante de una secuencia de aminoácido del mismo que comprende una extensión líder amino-terminal. También se describen formulaciones farmacéuticas que comprenden la composición y un método para el tratamiento del cáncer. Reivindicación 5: La composición de cualquiera de las reivindicaciones precedentes, donde el anticuerpo de HER2 de especie principal comprende secuencias de aminoácido variables livianas y variables pesadas en la SEC ID Nº 3 y 4, respectivamente. Reivindicación 15: La composición de la reivindicación 14, en la que la variante de glicosilación está seleccionada del grupo qu
